Happy Tau Day, everyone! Every June 28, a rogue fleet of math nerds makes its case for the abolition of arguably the most important irrational number in the world: pi. These men and women of the "tau" ...
PI-2620 is in Phase 3 development in Alzheimer’s disease by AC Immune’s partner, LMI This Fast Track designation applies across Alzheimer’s disease, progressive supranuclear palsy, and corticobasal ...
Lausanne, Switzerland, January 18, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that its ...
Next generation Tau tracer offers potential for earlier and more accurate diagnosis in Alzheimer’s and neurodegenerative diseases The clinical milestone highlights the strength of AC Immune’s Tau ...
University of Wyoming College of Engineering and Applied Science faculty members and students recently received awards from the Wyoming Alpha chapter of Tau Beta Pi, the national engineering honor ...
AC Immune (ACIU) Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease First Alzheimer’s patient imaged with PI-2620 in ADvance, the pivotal ...
The ADvance Phase 3 trial (ClinicalTrials.gov: NCT05641688) is an open-label, multi-center, non-randomized pivotal study to assess the efficacy and safety of PET imaging with [18F]PI-2620 for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results